Get the Stockscreener App
2.36
2.83%
0.065
After Hours:
2.40
0.04
+1.69%
Atossa Therapeutics Inc stock is traded at $2.36, with a volume of 34,657.
It is up +2.83% in the last 24 hours and up +25.53% over the past month.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
See More
Previous Close:
$2.295
Open:
$2.3
24h Volume:
34,657
Relative Volume:
0.24
Market Cap:
$23.54M
Revenue:
-
Net Income/Loss:
$-37.64M
P/E Ratio:
-0.5401
EPS:
-4.3698
Net Cash Flow:
$-33.40M
1W Performance:
-5.22%
1M Performance:
+25.53%
6M Performance:
-77.02%
1Y Performance:
-81.27%
1-Day Range:
$2.30
$2.45
1-Week Range:
$2.25
$2.60
52-Week Range:
$1.70
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
1448 NW MARKET STREET, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
2.36 | 22.89M | 0 | -37.64M | -33.40M | -4.3698 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
TradingKey - TradingKey
Atossa Therapeutics Inc (ATOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Atossa Therapeutics Inc (ATOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ATOS|Atossa Therapeutics Inc|Price:2.295|Chg%:-0.115 - TradingKey
ATOSSA THERAPEUTICS, INC. advances omics and organoid research in rare cancer field - Traders Union
Atossa Therapeutics (ATOS) Unveils Promising Data for (Z)-Endoxi - GuruFocus
Atossa Therapeutics (ATOS) Unveils Promising Data for (Z)-Endoxifen in Rare Disease Treatment - GuruFocus
Atossa Therapeutics highlights (Z)-endoxifen's dual action for rare McCune-Albright Syndrome treatment. - Pluang
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers - PR Newswire
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The News-Press
Price to sales forward of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
Enterprise value to revenue forward of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
Atossa Therapeutics Inc (ATOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Atossa Therapeutics sends Sandra S Hammer to AACR rare cancer event in Vancouver - Traders Union
ATOS Should I Buy - Intellectia AI
Price to cash flow ratio of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
ATOS Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Investor ReactionQuarterly Profit Report - dars.gov.et
ATOSSA THERAPEUTICS, INC. explores lessons from COVID-19 for future biosecurity strategies - Traders Union
Rodman & Renshaw Initiates Atossa Therapeutics(ATOS.US) With Buy Rating, Announces Target Price $12 - Moomoo
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - AOL.com
ATOS Initiates Coverage On Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Rodman & Renshaw initiates Atossa Genetics stock with buy rating By Investing.com - Investing.com South Africa
Rodman & Renshaw initiates Atossa Genetics stock with buy rating - Investing.com
ATOSAtossa Therapeutics Inc Short Interest - Finviz
Nona Biosciences Partners with Atossa Therapeutics to Advance Next-Generation Antibody Therapies for Breast Cancer - BioPharma APAC
Atossa Therapeutics raises $4.5M in registered direct offering By Investing.com - Investing.com Nigeria
Atossa Therapeutics (ATOS) Surges 5.7% as Biotech Momentum BuildsUnusual Call Volume - dars.gov.et
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Microcap Value Benchmark Index - marketscreener.com
Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell 3000E Index - marketscreener.com
Price to book forward of Atossa Therapeutics, Inc. – NASDAQ:ATOS - TradingView
Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell Microcap Index - marketscreener.com
Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell 3000E Growth Benchmark - marketscreener.com
Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell 3000E Value Benchmark - marketscreener.com
Atossa Therapeutics, Inc. adopts integrated biologic signals to advance breast cancer research - Traders Union
Price to sales forward of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Price to book forward of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Price to earnings forward of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Enterprise value to EBIT forward of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Enterprise value to EBITDA forward of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Atossa Therapeutics, Inc. (NASDAQ:ATOS): Are Analysts Optimistic? - simplywall.st
Atossa Therapeutics Inc (ATOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Atossa Therapeutics Inc (ATOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atossa Therapeutics Inc (ATOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Atossa Therapeutics Inc (ATOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Atossa Therapeutics Inc (ATOS) Institutional Confidence - TradingKey
Atossa Therapeutics Inc (ATOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Atossa Therapeutics brings medical innovation to Hudson Institute strategic discussions - Traders Union
Atossa Therapeutics (ATOS) Q1 2026 Earnings: Narrowing Losses with Positive EPS SurpriseRevenue Warning Signal - newsline.com
Atossa Therapeutics closes $4.5M registered direct offering By Investing.com - Investing.com Australia
Atossa's $16.5M Gambit: Fueling Cancer Trials in a Tough Biotech Market - BriefGlance
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):